Please assess the completion status of the following clinical trial:

Trial Title: A 12 Week Study to Assess Changes in Joint Inflammation Using Ultrasonography in Patients With Rheumatoid Arthritis (RA)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with adult-onset Rheumatoid Arthritis (RA) \>6 months and \<3 years~* Active RA~* Must have failed at least one disease modifying Anti Rheumatic Drug (DMARD) treatment~* Subject can have attempted no more than one previous Anti Tumor Necrosis factor (anti-TNF) and discontinued due to drug intolerance~Exclusion Criteria:~* Subject cannot have a second non-inflammatory musculoskeletal condition~* Subject cannot have a diagnosis of any other inflammatory arthritis~* Subject cannot have any previously infected prosthesis~* Subject cannot have arthroplasties in any of the joints assessed in the study~* Subject cannot have a history of chronic infections~* Subject cannot have known Tuberculosis (TB) disease, high risk of acquiring TB, or latent TB infection~* Subject cannot have a history of or current Lymphoproliferative disorder~* Subject cannot have known Human Immunodeficiency Virus (HIV) infection~* Subject cannot have received a live or attenuated vaccine within 8 weeks~* Subject cannot have current or history of malignancy~* Subject cannot have a history of blood disorders~* Subject cannot have a current or recent history of severe, progressive, and/or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological or cerebral disease~* Subjects must not have a history of adverse reaction to Polyethylene glycol (PEG), a protein medicinal product, or ultrasound gel applied to the skin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CZP 200 mg (Type: EXPERIMENTAL): Certolizumab Pegol (CZP) subcutaneous (sc) injections of 400 mg at Weeks 0, 2 and 4, followed by 200 mg at Weeks 6, 8 and 10.

Based on this trial design, predict the completion outcome and termination type (if applicable).